Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems

Area of Science:

• Infectious Diseases
• Cardiology
• Metabolic Disorders

Background:

• Infections, including human immunodeficiency virus (HIV), are linked to lipid metabolism disturbances and increased coronary heart disease (CHD) risk.
• HIV infection itself promotes hepatic lipogenesis and alters lipid profiles, with additional cardiovascular disease (CVD) risk amplified by lifestyle factors and comorbidities.
• Antiretroviral therapy (ART) can mitigate some risks but carries its own metabolic and cardiotoxic profiles.

Purpose of the Study:

• To highlight HIV-1's contribution to lipid alteration and inflammation.
• To examine the impact of antiretroviral therapy on cardiovascular risk in HIV-infected individuals.
• To discuss drug selection, statin/fibrate use, and switching strategies to minimize cardiovascular events.

Main Methods:

• Review of current literature and guidelines concerning HIV-1, lipid metabolism, and cardiovascular risk.
• Analysis of the effects of various antiretroviral drugs on lipid profiles and cardiotoxicity.
• Evaluation of treatment strategies, including early intervention and drug switching, to manage cardiovascular risk.

Main Results:

• HIV-1 significantly contributes to dyslipidemia and inflammation, increasing cardiovascular risk.
• Antiretroviral therapy, while essential, presents challenges due to drug-specific toxicities affecting lipid metabolism.
• The optimal timing for initiating HIV treatment to balance efficacy and cardiovascular safety remains unclear.

Conclusions:

• Early HIV treatment may reduce HIV's direct cardiovascular impact but could reveal drug-related adverse effects.
• The net effect of early treatment initiation on coronary heart disease and lipid abnormalities requires further investigation.
• Careful drug selection and management strategies are crucial for optimizing cardiovascular outcomes in the HIV-infected population.